NEW YORK, Nov. 14 – Belgian functional genomics company Galapagos Genomics said Wednesday that it had agreed to build a gene library for Pharmacia designed to help the pharmaceutical company to identify and validate drug targets for a range of diseases.
Galapagos has developed the PhenoSelect expression platform, which uses arrayed adenoviruses containing human genes to identify and validate targets.
"We are proud of the confidence that Pharmacia has expressed in our technology platform, and we feel strongly that this collaboration will result in an expedited identification and validation of novel drug targets for Pharmacia,” Onno van de Stolpe, Galapagos’ CEO, said in a statement.
Financial terms of the deal were not disclosed. Pharmacia of Peapack, NJ, was not immediately available to comment on the deal.
Galapagos’ other partners include Bayer, Vertex Pharmaceuticals, Incyte, Procter&Gamble, and the Netherlands Cancer Institute.